The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

Investors speculated on Covid vaccine firms. Despite the seasonal strength for flu-related vaccines ending, Moderna (MRNA) ...

Vaccine stocks received a major and sudden boost on January 7, 2025. Here's why these companies are experiencing tailwinds in ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.34% to 1,316.18 on the S&P Europe Select ADR Index. From continental Europe, the ...

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Vaccine makers, including ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more here.